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Abstract
Background: To date, data on the durability of a regimen of stavudine, lamivudine and nevirapine
are very limited, particularly from the resource-limited settings.
Methods: A prospective cohort study was conducted among 140 antiretroviral-naïve patients who
were enrolled to initiate d4T, 3TC and NVP between November 2004 and March 2005. The
objectives were to determine immunological and virological responses after 144 weeks of
antiretroviral therapy. Seventy patients with tuberculosis also received rifampicin during the early
period of antiviral treatment (TB group).
Results: Of all, median (IQR) baseline CD4 cell count was 31 (14–79) cells/mm3; median (IQR)
baseline HIV-1 RNA was 433,500 (169,000–750,000) copies/mL. The average body weight was 55
kilograms. By intention-to-treat analysis at 144 weeks, the overall percentage of patients who
achieved plasma HIV-1 RNA <50 copies/mL was 59.3% (83/140). In subgroup analysis, 61.4% (43/
70) patients in TB group and 57.1% (40/70) patients in control group achieved plasma HIV-1 RNA
<50 copies/mL (RR = 1.194, 95%CI = 0.608–2.346, P = 0.731). Eight (5.8%) patients discontinued
d4T due to neuropathy and/or symptomatic lactic acidosis.
Conclusion: The overall durability and efficacy of antiviral response of d4T, 3TC and NVP are
satisfied and they are not different between HIV-1 infected patients with and without co-
administration of rifampicin due to tuberculosis. However, stavudine-related adverse effects are
concerns.
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Background
Currently, the preferred first-line antiretroviral regimens
use a combination of two nucleoside reverse transcriptase
inhibitors (NRTIs) and either a non-nucleoside reverse
transcriptase inhibitor (NNRTI) or a ritonavir-boosted
protease inhibitor [1]. Although nevirapine is used as an
alternative to efavirenz for initial regimen in developed
countries, nevirapine has still been a key antiretroviral
drug in many resource-limited countries including Thai-
land due to its accessibility and affordability. In addition,
a component of stavudine and lamivudine is still widely
used as a backbone in the antiretroviral regimen in this
setting [2]. To date, data on the durability of a regimen of
stavudine, lamivudine and nevirapine are very limited,
particularly from the resource-limited settings.
In addition, HIV-1 infection has contributed to a signifi-
cant increase in the worldwide incidence of tuberculosis
and this has substantially affected the mortality [3,4].
Rifampicin is a key antituberculous drug. Unfortunately,
rifampicin is associated with a significant drug interaction
with nevirapine [5,6]. The results from previous studies
have shown that nevirapine 400 mg/day-based regimen
may be adequate to treat patients with tuberculosis and
receiving rifampicin [7-11]. Herein, we continued the pre-
viously described prospective pharmacokinetic study [12]
with the objectives to evaluate the treatment outcomes
after 144 weeks of antiretroviral treatment (ART) regard-
ing: (1) virological and immunological responses in all
patients; and comparison of responses between the
patients who received a regimen of stavudine, lamivudine
and nevirapine alone (control group) and the patients
with previous diagnosis of tuberculosis and concomitant
receiving of rifampicin during the early period of ART (TB
group) and (2) treatment outcomes of tuberculosis after
144 weeks of ART in TB group patient.
Methods
The study design was a prospective cohort study involving
140 HIV-infected Thai patients in the Bamrasnaradura
Infectious Diseases Institute, Ministry of Public Health,
Nonthaburi, Thailand. There were equally 70 patients in
TB group and control group. Initial enrollment was from
November 2004 to March 2005 as previously described
[12]. Inclusion criteria for the TB group were: (1) HIV-
infected individuals ≥15 years of age, (2) diagnosed active
TB by clinical features, positive acid-fast stain and/or pos-
itive culture for Mycobacterium tuberculosis, (3) receiving
rifampicin-containing anti-TB regimen ≥1 month prior to
enrollment, (4) CD4 cell count <350 cells/mm3 and (5)
willing to participate and give consent form. Inclusion cri-
teria for the control group were: (1) HIV-infected individ-
uals  ≥15 years of age (2) not receiving RFP within 1
month prior to enrollment, (3) CD4 cell count <350 cells/
mm3 and (4) willing to participate and give consent form.
Exclusion criteria for both two study groups was: (1) pre-
vious antiretroviral therapy, (2) pregnancy, (3) receiving a
medication that has drug-drug interactions with NVP or
RFP and (4) aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) >5 times of upper limit of normal
range. The administered antiretroviral drugs were stavu-
dine, lamivudine and nevirapine. All patients received
NVP 200-mg once-daily lead-in dose for 14 days, prior to
escalation to 200 mg twice daily. In the present study, the
patients in both groups were followed up through 144
weeks in which period of time they were assessed clini-
cally and evaluated for adverse events. CD4 cell counts
and plasma HIV-1 RNA were assessed every 12 weeks until
96 weeks of ART and then every 24 weeks through 144
weeks. The patients in TB group were repeatedly tested for
chest X-ray and clinically evaluated for tuberculosis at 144
weeks of ART. The institutional ethics committees of Bam-
rasnaradura Infectious Diseases Institute and Ministry of
Public Health approved the study. All patients signed the
inform consent.
The dosage of stavudine was adjusted by body weight (i.e.,
stavudine 30 mg and 40 mg twice a day for body weight
≤60 kg and >60 kg, respectively). The general characteris-
tics (e.g., gender, age, body weight, body mass index
(BMI), previous opportunistic infections and site of tuber-
culosis infection) were recorded. Blood samples were
obtained to study CD4 cell counts by flow cytometry and
HIV-1 RNA by polymerase chain reaction using Roche
Amplicor® version 1.5 (Roche Diagnostics, Branchburg,
NJ, U.S.A.); lower limit of HIV-1 RNA detection, 50 cop-
ies/ml. The virological failure was defined as either a
rebound plasma HIV-1 RNA of >1,000 copies/mL after
having previously undetectable value or lack of achieve-
ment to <50 copies/mL at 24 weeks of ART. Genotypic
resistance testing (TRUGENE HIV-1 Genotyping Assay,
Visible Genetics Inc., Toronto, Canada) was performed
after the patient was documented virological failure.
Anti-tuberculosis regimen included isoniazid, rifampicin,
ethambutol and pyrazinamide were administered in the
first two months followed by isoniazid and rifampicin for
the subsequent four months. Tuberculosis treatment out-
comes (cure, treatment completed, treatment failure)
were evaluated by using definitions from WHO and the
European Region of the International Union Against
Tuberculosis and Lung Disease (IUATLD) [13].
Power and Sample Size version 1.01 [14] was used to cal-
culate sample size by testing for equivalence of plasma
NVP level as previously described [12]. A chi-square test
was used to compare the number of patients who achieve
undetectable HIV-1 RNA between groups. P value < 0.05
was considered as statistically significant. All analyses
were performed using SPSS version 11.5.BMC Infectious Diseases 2008, 8:136 http://www.biomedcentral.com/1471-2334/8/136
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Results
A total of 140 patients were eligible and initially enrolled
to the study. Seventy patients were equally included in
each group. The patients' general characteristics, baseline
CD4 counts and plasma HIV-1 RNA of each group are
shown in table 1. Of 70 patients in TB group, 31 (44.3%),
20 (28.6%), 14 (20%), 3 (4.3%), 2 (2.9%) patients were
diagnosed pulmonary tuberculosis, disseminated tuber-
culosis, cervical tuberculous lymphadenitis, gastrointesti-
nal tuberculosis and tuberculous meningitis, respectively.
By intention-to-treat analysis, the overall percentage of
patients who achieved plasma HIV-1 RNA <50 copies/mL
at 144 weeks was 59.3% (83 of 140). Figure 1 shows pro-
portion of the patients who achieved undetectable plasma
HIV-1 RNA at each time point by intention-to-treat analy-
sis and on-treatment analysis. In subgroup analysis,
61.4% (43 of 70) patients in TB group and 57.1% (40 of
70) patients in control group achieved plasma HIV-1 RNA
<50 copies/mL (RR = 1.194, 95%CI = 0.608–2.346, P =
0.731). Mean CD4 cell count response is shown in figure
2.
Of all, 57 patients needed to discontinue ART after 144
weeks of ART, 27 patients were in TB group and 30
patients were in control group. There was no difference in
term of ART discontinuation between the two groups (P =
0.688). The reasons were as follow: lost to follow-up (14
patients, 10.0%), HIV drug resistance (13, 9.3%), NVP-
related skin rashes grade II-III (11, 7.9%), d4T-related
neuropathy and/or symptomatic lactic acidosis (8, 5.8%),
deceased (7, 5.0%), transferred care (3, 2.1%) and drug
interaction due to receiving itraconazole (1, 0.7%),
respectively. Of 70 patients in each group, 10% (7 of 70)
and 9% (6 of 70) patients in the TB group and control
group developed HIV-1 RNA >1,000 copies/mL, respec-
tively (P = 1.000). Among 13 patients with drug resist-
ance, 5 (38%) had mutations contributed to only NRTI
resistance; 1 (8%) had mutations contributed to only
NNRTI resistance; and 7 (54%) patients had mutations
contributed to both NRTI and NNRTI resistance. For
NRTI-resistance mutations, M184V/I was the most com-
mon (10 of 13, 77%). Thymidine analogue associated
mutations (TAMs) were found in 1 (8%) patients. K65R
was observed in 2 of 13 (15%) patients. For NNRTI-resist-
ance mutations, there were Y181C/I (8 of 13, 61%) and
K103N (1 of 13, 8%) as shown in figure 3. There were no
differences in terms of NRTI and NNRTI-resistance associ-
ated mutations between the two subgroups (P > 0.05).
In term of treatment outcomes of 70 patients in TB group,
55 (79%) patients were cured or completed treatment; 7
(10%) lost to follow-up; 5 (7%) deceased (from MAC
infection, TB paradoxical reaction and severe wasting for
each patient); 2 (3%) transferred care; and 1 (1%) had
relapse.
Proportion of patients who achieved undetectable plasma HIV-1 RNA <50 copies/mL Figure 1
Proportion of patients who achieved undetectable plasma HIV-1 RNA <50 copies/mL.
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Discussion
The present study has demonstrated that an antiretroviral
regimen of stavudine, lamivudine and nevirapine showed
acceptable long-term antiviral effectiveness in advanced
HIV-1 infected patients. By intention-to-treat analysis,
approximately 60% patients still achieve undetectable
plasma HIV-1 RNA through 144 weeks. Consequently,
CD4 cell count continues to increase significantly over the
study period. This is considered favorable outcome when
compared to the other NNRTI-based regimen [15-17]. In
subgroup analysis, we can not find any discrepancy of
antiviral response between HIV-infected patients who pre-
viously received rifampicin and those who did not
received rifampicin. This confirms the previous published
short-term efficacy data in these patients [12,18]. Average
mean trough plasma nevirapine levels of week 8 and week
12 was 5.40 mg/l in the TB group and 6.56 mg/l in control
group (P = 0.048) [12]. Although minimum plasma con-
centration of nevirapine is somewhat different during the
early period of ART between the two subgroup patients as
mentioned, the long-term antiviral responses between
these two groups were not different as demonstrated in
the present study. In addition, the prevalence of Y181C/I,
K103N and other mutations that confer resistant to
NNRTIs were not different between the two groups when
virological failure was detected. However, therapeuric
nevirapine level may be needed to verify in the further
study.
Long-term acceptability and safety may be a concerned
issue for this regimen. It is well established that long-term
administration of NRTI, particularly stavudine, can cause
mitochondrial toxicity. The clinical manifestations of this
adverse effect present as hyperlactatemia and polyneurop-
athy [19]. In the present cohort, 5.8% of patients subse-
quently developed stavudine-associated toxicity and
needed to substitute stavudine with other NRTI. A 2008
ART guideline that developed by the Department of
Health and Human Services (DHHS) panel no longer rec-
ommends the component of stavudine combined with
lamivudine as a backbone NRTIs for initial therapy in
treatment-naïve patients [1]. Thus, zidovudine and teno-
fovir could be the options in this area. Nevertheless, the
frequency and severity of adverse events associated with
the use of zidovudine are greater in patients with
advanced disease at the time of initiation of therapy [20].
Likewise, tenofovir is more expensive and less available.
This brings to a concern of an appropriate backbone NRTI
in the first-line regimen in resource-limited countries. To
date, World Health Organization (WHO) has not yet
updated its guidelines for the use of ART in the countries
with constrained resources since 2006 [21]. According to
these limitations and until the other options are more
accessible; stavudine is still a component drug in the treat-
ment guidelines for the resource-limited countries. Con-
versely, strategic treatment to minimize long-term toxicity
of stavudine, such as switching to other drugs at an opti-
mal timing, should be evaluated further.
Mean CD4 cell count between TB and control groups Figure 2
Mean CD4 cell count between TB and control groups.
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Table 1: Baseline characteristics of 140 HIV-infected patients
Characteristics Total (n = 140) TB Group (n = 70) Control Group (n = 70) P value
Gender: Male 95 (68%) 56 (80%) 39 (56%) 0.002
Age, years, mean ± SD 35.7 ± 7.6 34.4 ± 6.2 37.2 ± 8.7 0.028
Body weight, Kgs, mean ± SD 54.6 ± 9.6 54.7 ± 8.7 54.4 ± 10.6 0.827
Body mass index, mean ± SD 20.1 ± 2.9 19.7 ± 2.4 20.5 ± 3.4 0.097
CD4 cell counts, cells/mm3, mean ± SD 62 ± 74 61 ± 74 76 ± 75 0.823
%CD4, median (IQR) 5 ± 5 6 ± 5 5 ± 5 0.226
Plasma HIV RNA, copies/ml, median (IQR) 433,500 (169,000–750,000) 505,000 (269,000–750,000) 291,000 (94,600–714,000) 0.014
Plasma HIV RNA, Log copies/ml, median (IQR) 5.6 (5.2–5.9) 5.7 (5.4–5.9) 5.6 (5.0–5.9) 0.004
ALP, mg/dl, median (IQR) 98 (71–142) 110 (75–154) 91 (70–128) 0.072
AST, U/l, median (IQR) 30 (20–50) 36 (27–60) 35 (26–47) 0.371
ALT, U/l, median (IQR) 27 (19–42) 27 (18–51) 32 (22–49) 0.169
Total bilirubin, mg/dl, median (IQR) 0.6 (0.4–0.7) 0.6 (0.5–0.8) 0.5 (0.4–0.7) 0.051
IQR = interquartile range
Drug resistance mutations in patients with virological failure Figure 3
Drug resistance mutations in patients with virological failure.
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The initial sample size of the present study is calculated
from the difference of minimum plasma concentration of
nevirapine between the two groups of patients [12]. Thus,
it may not be enough to detect the difference of long-term
antiviral responses. Another limitation is that many stud-
ies showed the impact of genetic polymorphism on NVP
metabolism [22,23]. Thus, this result should be cautiously
applied with the other ethnic population.
Conclusion
In conclusion, a regimen of stavudine, lamivudine and
nevirapine provides the satisfied durability and immuno-
logical response in very advanced HIV-infected patients.
There is no difference of the 144-week efficacy between
HIV-1 and tuberculosis co-infected patients receiving
rifampicin and HIV-1 mono-infection not receiving
rifampicin. However, long-term safety of stavudine is a
concern. Relapse rate after 3 years of initiation of tubercu-
losis treatment in the patients who are receiving ART is
low. In resource-limited settings, a regimen of stavudine,
lamivudine and nevirapine is still an important first-line
option for advanced HIV-1 infected patients. Strategy to
minimize long-term toxicity of stavudine, such as switch-
ing to other drugs at an optimal timing, should be evalu-
ated further.
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